Horizon Therapeutics (HZNP) Misses Q1 EPS by 13c, Offers FY Guidance

May 5, 2021 7:12 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Horizon Therapeutics (NASDAQ: HZNP) reported Q1 EPS of $0.03, $0.13 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $342.4 million versus the consensus estimate of $382.14 million.

GUIDANCE:

Horizon Therapeutics sees FY2021 revenue of $2.75-2.85 billion, versus the consensus of $2.81 billion.

  • The Company now expects full‐year 2021 net sales to range between $2.75 billion and $2.85 billion, updated from the previous range of $2.70 billion and $2.80 billion. Full-year 2021 adjusted EBITDA is now expected to range between $1.02 billion and $1.06 billion, updated from the previous guidance of $1.14 billion and $1.18 billion. The updated guidance ranges incorporate Viela, which was acquired on March 15, 2021. The Company continues to expect TEPEZZA full-year 2021 net sales of greater than $1.275 billion and KRYSTEXXA full-year 2021 net sales of greater than $500 million.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings